KURA Kura Oncology, Inc. Insider Trading

CMO Mollie Leoni sold 84,929 shares of KURA at $9.82 (2026-06-18) via 10b5-1 plan; retains 182,345 shares.

Mollie Leoni, Chief Medical Officer, sold 84,929 shares at $9.82 on 2026-06-18 as part of a pre-arranged 10b5-1 trading plan adopted on 2026-03-19, reducing her holdings by 31.8% from 267,274 shares to 182,345 shares. The transaction is scheduled rather than discretionary, removing any inference about insider conviction or market timing. KURA is currently unprofitable with net income of $-73,333,000.00 on quarterly revenue of $18,265,000.00, though the company showed annual revenue growth of 25.2%. The stock traded at $9.82 during the sale and currently stands at $10.36, approximately 17.0% below its 52-week high of $12.49. The scheduled nature of this sale under a pre-arranged plan precludes characterization of timing or strategic motivation; investors should focus on the reduction in management holdings and the company's ongoing losses rather than transaction signals.

KURA CEO Wilson Troy Edward purchased 50,000 shares at $8.20 on 2025-09-08, doubling stake to 100,968 shares amid 44.6% 30-day rally.

Wilson Troy Edward, President & CEO of Kura Oncology, purchased 50,000 shares at $8.20 for $410,145.00, increasing his holdings from 50,968 to 100,968 shares—a 98.1% increase in his position. This buy occurred while the stock was trading -62.0% from its 52-week high of $21.08, though the stock has rebounded 44.6% over the prior 30 days. The purchase represents his second discretionary buy at KURA in rapid succession (following an acquisition on 2025-08-13); prior sales at this ticker yielded a -7.4% 90-day average return, suggesting previous exits were well-timed at the ticker-specific level. The company remains unprofitable (net income of $-66,122,000.00 over the most recent full fiscal year) with trailing-twelve-month revenue of only $15,288,000.00 against a $695,245,451.85 market cap, positioning the stake accumulation against a backdrop of significant financial burn and valuation pressure.

KURA CEO Troy Edward Wilson purchases 50,000 shares (5165.3% increase) at blended $6.06 in two transactions

On 2025-08-12 and 2025-08-13, Troy Edward Wilson, President and CEO of Kura Oncology, made 2 separate purchases totaling 50,000 shares for $303,201.45 at prices of $5.85 and $6.64 respectively (blended average $6.06), increasing his holdings from 968 shares to 50,968 shares—a net increase of 5165.3%. This transaction represents a material and discretionary commitment of capital by the chief executive during a period when KURA trades at -68.7% from its 52-week high of $21.08. The company remains unprofitable, with a most recent quarter revenue of $15,288,000 offset by net income of -$66,122,000, yet the CEO initiated this substantial purchase immediately after the stock had recovered +7.7% over the prior 30 days. At his prior ticker (KURA), the insider had executed 2 sells on 2024-01-24, both of which proved well-timed at the 90-day mark, though his broader cross-ticker sell track record (8 prior sells) shows an average 90-day return of -7.4%, suggesting mixed timing skill in the open market.